LaNova Medicines' LM-305 Receives IND Acceptance by China NMPA

SHANGHAI, September 2, 2022 – LaNova Medicines announced that the New Drug Clinical Trial (IND) application for its GPRC5D-targeting antibody conjugate drug LM-305 project has been accepted by the National Medical Products Administration (NMPA). Previously, the US Food and Drug Administration (FDA) had approved LM-305 to conduct clinical trials in the US in July 2022.

About LM-305

LM-305 is the second antibody-drug conjugate developed by LaNova Medicines based on its proprietary discovery platform. At present, it is the first GPRC5D-targeting antibody-drug conjugate to enter the clinical stage in the world.

About GPRC5D

GPRC5D (G protein-coupled receptor, class C, group 5, member D) is a member of the G protein-coupled receptors (GPCRs) family. As a novel GPCR drug target, GPRC5D is an orphan receptor for which no endogenous ligand has been found so far. GPRC5D is mainly expressed in malignant bone marrow plasma cells and hair follicles, but little or no expression in normal tissues. Studies have shown that GPRC5D is specifically highly expressed in multiple myeloma (MM) cells, and the expression level is relatively independent of BCMA, another target for multiple myeloma. Therefore, GPRC5D is expected to become the next treatment target for relapsed and refractory multiple myeloma (RRMM). As the first GPRC5D-directed ADC to enter the clinical development stage, LM-305 has the potential to become a first-in-class molecule.